HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management
Abstract Human papillomavirus (HPV)-positive (HPV+) oropharyngeal squamous cell
carcinoma (OPSCC) has one of the most rapidly increasing incidences of any cancer in high …
carcinoma (OPSCC) has one of the most rapidly increasing incidences of any cancer in high …
Therapeutic cancer vaccines
Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …
understanding of the breadth of tumour-associated antigens, the native immune response …
[HTML][HTML] Biological and clinical aspects of HPV-related cancers
KA Szymonowicz, J Chen - Cancer biology & medicine, 2020 - ncbi.nlm.nih.gov
Cancer-related diseases represent the second overall cause of death worldwide. Human
papilloma virus (HPV) is an infectious agent which is mainly sexually transmitted and may …
papilloma virus (HPV) is an infectious agent which is mainly sexually transmitted and may …
Cervical cancer immunotherapy: facts and hopes
It is a sad fact that despite being almost completely preventable through human
papillomavirus (HPV) vaccination and screening, cervical cancer remains the fourth most …
papillomavirus (HPV) vaccination and screening, cervical cancer remains the fourth most …
A comparison of plasmid DNA and mRNA as vaccine technologies
MA Liu - Vaccines, 2019 - mdpi.com
This review provides a comparison of the theoretical issues and experimental findings for
plasmid DNA and mRNA vaccine technologies. While both have been under development …
plasmid DNA and mRNA vaccine technologies. While both have been under development …
Immunotherapy for head and neck cancer: Recent advances and future directions
JD Cramer, B Burtness, RL Ferris - Oral oncology, 2019 - Elsevier
Three randomized phase III trials have now conclusively proven that exposure to a PD-1
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …
Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy
M Canning, G Guo, M Yu, C Myint… - Frontiers in cell and …, 2019 - frontiersin.org
Head and neck squamous cell carcinomas (HNSCCs) are highly aggressive, multi-factorial
tumors in the upper aerodigestive tract affecting more than half a million patients worldwide …
tumors in the upper aerodigestive tract affecting more than half a million patients worldwide …
Therapeutic cancer vaccines: advancements, challenges, and prospects
T Fan, M Zhang, J Yang, Z Zhu, W Cao… - Signal Transduction and …, 2023 - nature.com
With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …
cell therapies, cancer immunotherapy has undergone a profound transformation over the …
Translational genomics and recent advances in oral squamous cell carcinoma
Oral squamous cell carcinomas (OSCC) are a heterogeneous group of cancers arising from
the mucosal lining of the oral cavity. A majority of these cancers are associated with lifestyle …
the mucosal lining of the oral cavity. A majority of these cancers are associated with lifestyle …
An update on the immune landscape in lung and head and neck cancers
Immunotherapy has dramatically changed the treatment landscape for patients with cancer.
Programmed death–ligand 1/programmed death‐1 checkpoint inhibitors have been in the …
Programmed death–ligand 1/programmed death‐1 checkpoint inhibitors have been in the …